Effect of ciprofibrate on C-reactive protein and fibrinogen levels

Angiology

Volumn 53, Issue 3, 2002, Pages 273-277

  Rizos, Evagelos ^a   Kostoula, Angeliki ^a   Elisaf, Moses ^a   Mikhailidis, Dimitri P ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; CIPROFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; FIBRINOGEN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIPID BLOOD LEVEL; PROTEIN BLOOD LEVEL;

ANTILIPEMIC AGENTS; C-REACTIVE PROTEIN; CLOFIBRIC ACID; FEMALE; FIBRINOGEN; HUMANS; HYPERLIPIDEMIAS; MALE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0036090215     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970205300304     Document Type: Article

References (23)

1. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
2. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
3. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-age men: Results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992
4. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: Results from the cardiovascular health study and the rural health promotion project
5. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
6. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
7. Measurement of C-reactive protein for the targeting in the primary prevention of acute coronary events
8. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
9. Long-term effects of pravastatin on plasma concentration of C-reactive protein
10. Effect of statins on C-reactive protein in patients with coronary artery disease
11. Treatment of dyslipidaemias in patients with established vascular disease: A revival of the fibrates
12. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
13. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
14. Effects of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels
15. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin alone and in combination treatment
16. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: A pilot study
17. Statin + fibrate combination therapy: Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease
18. The effect of atorvastatin on serum lipids, lipoprotein (a) and plasma fibrinogen levels in primary dyslipidaemia - A pilot study involving serial sampling
19. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: Response to ciprofibrate of lifestyle advice
20. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia
21. Effect of hypertension, and its treatment, on lipid, lipoprotein (a), fibrinogen and bilirubin levels in patients referred for dyslipidaemia
22. Do HMG-CoA reductase inhibitors affect fibrinogen?